There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Vascular Biogenics (VBLT) with bullish sentiments.
Biogen (BIIB)
In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on Biogen, with a price target of $390.00. The company’s shares closed last Thursday at $338.34.
According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -12.3% and a 32.7% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Enanta Pharmaceuticals.
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $345.52.
See today’s analyst top recommended stocks >>
Vascular Biogenics (VBLT)
In a report released yesterday, Kevin DeGeeter from Oppenheimer maintained a Buy rating on Vascular Biogenics, with a price target of $3.00. The company’s shares closed last Thursday at $1.38.
According to TipRanks.com, DeGeeter is a 4-star analyst with an average return of 7.3% and a 42.4% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Molecular Templates, and Cidara Therapeutics.
Currently, the analyst consensus on Vascular Biogenics is a Strong Buy with an average price target of $3.44, a 164.6% upside from current levels. In a report issued on April 2, H.C. Wainwright also maintained a Buy rating on the stock with a $3.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
